Adjunct to antineoplastic therapy 5 mcg/kg starting not <24 hr after the last dose of antineoplastic, by single SC inj daily, continuous IV or SC infusion, or by IV infusion over 15-30 min. Continue treatment until neutrophil count is stabilized w/in the normal range which may take up to ≥14 days.
Reduce incidence of neutropenia associated w/ antineoplastic therapy A formulation of filgrastim conjugated w/ monomethoxy polyethylene glycol given SC in a single dose of 6 mg, not <24 hr after the last dose of antineoplastic.
Bone marrow transplantation Initially 10 mcg/kg daily by IV infusion over 30 min or 4 hr, or by continuous IV or SC infusion over 24 hr.
Mobilisation of peripheral blood progenitor cells 10 mcg/kg as single SC inj daily or by continuous infusion for 4-7 days until leucapheresis.
After myelosuppressive chemotherapy 5 mcg/kg by SC inj daily.
Patient w/ congenital neutropenia Initially 12 mcg/kg daily.
Patient w/ idiopathic or cyclic neutropenia Initially 5 mcg/kg daily. Doses are administered SC in single or divided doses.
Patient w/ HIV infection & persistent neutropenia Initially 1 mcg/kg by SC inj daily. Max: 4 mcg/kg daily. Maintenance: 300 mcg daily for 1-7 days a wk.
Sign Out
